Clinical Trials on Metastatic Small Cell Lung Cancer

Total 20679 results

Eli Lilly and Company

Withdrawn

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Metastatic Squamous Non-Small Cell Lung Cancer | Locally Advanced Squamous Non-Small Cell Lung Cancer

Italy, Romania, Germany, Belgium, Russian Federation, United States, United Kingdom
Latin American Cooperative Oncology Group
Janssen, LP

Recruiting

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations (AMIGO-1)

Metastatic Non-small Cell Lung Cancers

Brazil
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

Australia, Russian Federation, United States, Argentina, Austria, Belgium, Brazil, Chile, France, Germany, Italy, Mexico, Poland, Romania, Spain, Switzerland, United Kingdom, Ireland, Netherlands
Luye Pharma Group Ltd.

Unknown

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

China
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
Intergroupe Francophone de Cancerologie Thoracique

Completed

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

Non Small Cell Lung Cancer Metastatic | HER2 Gene Mutation | Non Small Cell Lung Cancer Stage III

France
National Cancer Institute, Naples

Active, not recruiting

MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer (MILES-4)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Italy
Seoul National University Hospital
MACROGEN

Unknown

Cancer Panel From Blood of Lung Cancer Patients (CAPABLE)

Non Small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Recurrent

Korea, Republic of
Uptake Medical Technology, Inc.

Not yet recruiting

Vapor Ablation for Localized Cancer Lesions (VAPORIZED)

Lung Cancer | Non Small Cell Lung Cancer | Metastatic Lung Cancer

Austria, Italy
Aetion, Inc.

Completed

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

Metastatic Lung Cancer | Non-small Cell Lung Cancer

United States
Uptake Medical Technology, Inc.

Completed

Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE) (VAPORIZE)

Lung Cancer | Non Small Cell Lung Cancer | Metastatic Lung Cancer

Australia
Alliance Foundation Trials, LLC.
Bristol-Myers Squibb; Celgene Corporation

Terminated

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Nonsmall Cell Lung Cancer | Non Small Cell Lung Cancer Recurrent | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Non-Small-Cell Lung Cancer Metastatic

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Lung Neuroendocrine Neoplasm | Metastatic Malignant Neoplasm in the Brain | Metastatic Lung Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Not yet recruiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Metastatic Melanoma | Locally Advanced Melanoma | Metastatic Alveolar Soft Part Sarcoma | Metastatic Non Small Cell Lung Cancer | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma | Metastatic Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer | Locally... and other conditions

United States
Stanford University
The American Association of Physicists in Medicine

Terminated

Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors

Pancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...

United States
Memorial Sloan Kettering Cancer Center

Recruiting

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Non Small Cell Lung Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Metastatic Non-Small Cell Lung Carcinoma

United States
Joel Neal
Nektar Therapeutics

Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Tumors Metastatic to Brain | Stage IV Non-small Cell Lung Cancer (NSCLC) | Recurrent Non-small Cell Lung Cancer (NSCLC) | Extensive-stage Small Cell Lung Cancer (SCLC) | Recurrent Small Cell Lung Cancer (SCLC) | Metastatic Breast Cancer (mBC)

United States
Verastem, Inc.
Mirati Therapeutics Inc.

Recruiting

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung | Malignant Neoplastic Disease | KRAS Activating Mutation

United States
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
University Health Network, Toronto
Princess Margaret Hospital, Canada

Recruiting

Stereotactic Radiotherapy (SBRT) of Lung Metastasis

Non-small Cell Lung Cancer | Metastasis From Other Cancers

Canada
Necmettin Erbakan University
Health Institutes of Türkiye (TUSEB)

Not yet recruiting

The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients

Metastatic Non-small Cell Lung Cancer

Turkey
NovoCure GmbH

Not yet recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)

Metastatic Non-small Cell Lung Cancer
AstraZeneca

Recruiting

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. (eVOLVE-Lung02)

Metastatic Non-small Cell Lung Cancer

Spain, Italy, Australia, United Kingdom, Korea, Republic of, Belgium, Canada, Germany, Argentina, United States, Brazil, India, Japan, France, Taiwan, Thailand, Turkey, Mexico, Hungary, China, Poland, Austria, South Africa, Czechia, Slo... and more
Daiichi Sankyo
Merck Sharp & Dohme LLC; AstraZeneca

Recruiting

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

Metastatic Non Small Cell Lung Cancer

United States, China, Belgium, Portugal, Japan, Taiwan, France, United Kingdom, Spain, Hungary, Thailand, Germany, Italy, Switzerland, Hong Kong, Korea, Republic of, Australia, Mexico, Brazil, Netherlands, Romania, Argentina, Chile, G... and more
Sophia Genetics SAS

Recruiting

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer (DEEP-Lung-IV)

Non-small Cell Lung Cancer Metastatic

United States, Spain, France, Israel, Germany, Canada, Italy, Brazil
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

Non Small Cell Lung Cancer Metastatic

France
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Metastatic Non-Small Cell Lung Cancer

Poland, United States, Argentina, Austria, Brazil, Chile, China, Colombia, France, Germany, Israel, Japan, Korea, Republic of, Mexico, Spain, Taiwan, Thailand, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

Metastatic Non-small Cell Lung Cancer

Japan
Intergroupe Francophone de Cancerologie Thoracique

Active, not recruiting

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE)

Non Small Cell Lung Cancer Metastatic

France
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
UNICANCER
AstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC

Completed

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung)

Non-small Cell Lung Cancer Metastatic

France
AIO-Studien-gGmbH
Merck Sharp & Dohme LLC

Terminated

Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC) (PRIMUS)

Metastatic Squamous Non-small Cell Lung Cancer

Germany
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital; Acea Bio (Hangzhou) Co., Ltd.

Active, not recruiting

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC

Metastatic Non-small Cell Lung Cancer

China
MedPacto, Inc.
AstraZeneca

Unknown

Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC

Non-Small Cell Lung Cancer Metastatic

Korea, Republic of
Sichuan University
Chengdu MedGenCell, Co., Ltd.

Completed

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

Almonertinib With Chemotherapy in mEGFR NSCLC

Non-Small Cell Lung Cancer Metastatic

China
R-Pharm

Completed

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Advanced/Metastatic Non-Small Cell Lung Cancer

Germany, Korea, Republic of, Russian Federation, Taiwan, Australia, Italy, France, United States, Argentina, Spain
PeriPharm
Jewish General Hospital; Personalized Medicine Partnership for Cancer

Terminated

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Non-small Cell Lung Cancer Metastatic

Canada
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC. (NA_00067809)

Non-small Cell Lung Cancer Metastatic

United States
National Guard Health Affairs

Suspended

Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer (TAXIS01)

Non-small Cell Lung Cancer Metastatic

Saudi Arabia
National Guard Health Affairs

Suspended

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (REALME)

Non-small Cell Lung Cancer Metastatic

Saudi Arabia
Institut Cancerologie de l'Ouest

Recruiting

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy (TRAILOCLORI01)

Metastatic Non Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer

France
Daiichi Sankyo
AstraZeneca

Available

Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients

Advanced Non-Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Austria, Spain
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Metastatic Non Small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Intergroupe Francophone de Cancerologie Thoracique
ANRS, Emerging Infectious Diseases

Completed

Immunotherapy by Nivolumab for HIV+ Patients (CHIVA2)

HIV/AIDS | Non Small Cell Lung Cancer Stage IIIB | Non Small Cell Lung Cancer Metastatic

France
Chonnam National University Hospital
Roche Pharma AG

Completed

A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response (MENTOR)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

Korea, Republic of
Fox Chase Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Recurrent

United States
Xuanzhu Biopharmaceutical Co., Ltd.

Recruiting

A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung Cancer

China
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer

Clinical Trials on Metastatic Small Cell Lung Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations